HPV vaccination and cervical cancer

Current Oncology Reports

Volumn 14, Issue 6, 2012, Pages 559-567

  Szarewski, Anne ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bivalent vaccine; Cervarix ; Cervical cancer; Gardasil ; HPV vaccine; Human papillomavirus; Quadrivalent vaccine

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; VIRUS ANTIBODY; WART VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CANCER GRADING; CONDYLOMA ACUMINATUM; CROSS PROTECTION; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FETUS DISEASE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INJECTION SITE REACTION; PAPILLOMAVIRUS INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SERODIAGNOSIS; SPONTANEOUS ABORTION; TREATMENT INDICATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VULVOVAGINAL DISEASE; VULVOVAGINAL NEOPLASIA; WOMEN'S HEALTH;

ADOLESCENT; CROSS PROTECTION; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84870542252     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0259-3     Document Type: Article

References (86)

1. Jemal A, Bray F, Center MM, Ferlay J, et al. Global cancer statistics: GLOBOCAN 2008. CA Cancer J Clin. 2011;61:69-90.
2. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-32.
3. Capri S, Gasparini R, Panatto D, et al. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles. Gynecol Oncol. 2011;121:514-21.
4. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-56.
5. Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine. 2008;26 Suppl 10:K17-28.
6. Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:123-37.
7. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24 Suppl 3:S3/35-41.
8. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol. 2010;117:S5-10.
9. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol. 2008;110:S1-10.
10. Excellent explanation of immune mechanisms in HPV infection. 10. Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and 18 infections. J Natl Cancer Inst. 2010;102:1653-62.
11. Castellsague X. Risk of new infection with the same HPV type in women with naturally acquired HPV 16/18 antibodies (abstract No 44). 13th Biennial meeting of the International Gynaecologic Cancer Society (IGCS); 2010 Oct 23-26; Prague; 2010 Oct 23-26.
12. Schwarz TF, Kocken M, Petaja T, et al. Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine. Hum Vaccin. 2010;6:1054-61.
13. Haupt RM, Sings HL. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil. J Adolesc Health. 2011;49:467-75.
14. Petaja T, Pedersen C, Poder A, et al. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer. 2011;129:2147-57.
15. Rivera Medina DM, Valencia A, de Velasquez A, et al. Safety and immunogenicity of the HPV 16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J Adolesc Health. 2010;46:414-21.
16. Romanowski B. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009;374:1975-85.
17. Roteli-Martins CM, Naud P, Borba P, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: follow up to 8.4 years. Abstract. Presented at EPSID, Nice, 2010.
18. Naud PRMC, De Carvalho N, Teixeira J, Borba P et al. HPV-16/18 Vaccine: Sustained Immunogenicity And Efficacy Up To 9.4 Years. IPV Conference, Sept 17-22 2011 Berlin; 2011. p. Abstract number O-18.04
19. Schwarz TF, Huang LM, Medina DM, et al. Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10-14 Years. J Adolesc Health. 2012;50:187-94.
20. Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin. 2011;7:1343-58.
21. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin. 2011;7:1359-73. The direct comparison trial of the two vaccines.
22. Brown DR, Garland SM, Ferris DG, et al. The humoral response to Gardasil(R) over four years as defined by Total IgG and competitive Luminex immunoassay. Hum Vaccin. 2011;7:1-9.
23. David MP, Van Herck K, Hardt K, et al. Long-term persistence of anti-HPV-16 and 18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol. 2009;115:S1-6.
24. Syrjanen K. Persistent high-risk human papillomavirus (HPV) infections as surrogate endpoints of progressive cervical disease. Potential new endpoint for efficacy studies with new-generation (non-HPV 16/18) prophylactic HPV vaccines. Eur J Gynaecol Oncol. 2011;32:17-33.
25. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol. 2008;110:S18-25.
26. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301-14.
27. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia grade 3 or greater: endof-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:89-99. End of study results of the Cervarix ® Phase III trial.
28. Kreimer AR, Gonzalez P, Katki HA, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol. 2011;12:862-70.
29. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila Pa). 2009;2:868-78. The final results of the Gardasil trials showing vaccine efficacy against high grade disease.
30. Brown DR, Kjaer SK, Sigurdsson K, et al. The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPVNaive Women Aged 16-26 Years. J Infect Dis. 2009;199:926-35.
31. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341: c3493.
32. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377:2085-92. The first evidence of population efficacy of HPV vaccination, showing a reduction in high grade cervical disease.
33. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11:39-44.
34. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-55.
35. Wheeler CM, Castellsague X, Garland SM, et al. Crossprotective efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: end-of-study (4-year) analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:100-10. The end of study cross-protection data, with detailed discussion of the cross-protection issue.
36. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years. J Infect Dis. 2009;199:936-44.
37. Bulkmans NW, Bleeker MC, Berkhof J, et al. Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer. 2005;117:177-81.
38. Insinga RP, Perez G, Wheeler CM, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev. 2011;20:287-96.
39. Wheeler CM, Hunt WC, Joste NE, et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009;101:475-87.
40. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and typespecific implications in cervical neoplasia. Vaccine. 2008;26 Suppl 10:K1-16.
41. Bonanni P, Cohet C, Kjaer SK, et al. A summary of the postlicensure surveillance initiatives for GARDASIL/SILGARD. Vaccine. 2010;28:4719-30.
42. Omer SB. Safety of quadrivalent human papillomavirus vaccine. J Intern Med. 2012;271:177-8.
43. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009;5:332-40.
44. Verstraeten T, Descamps D, David MP, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 2008;26:6630-8.
45. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009;5. The direct comparison trial of the two vaccines
46. Wacholder S, Chen BE, Wilcox A, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ. 2010;340:c712.
47. Pomfret TC, Gagnon Jr JM, Gilchrist AT. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. J Clin Pharm Ther. 2011;36:1-9.
48. Markowitz LE, Hariri S, Unger ER, et al. Post-licensure monitoring of HPV vaccine in the United States. Vaccine. 2010;28:4731-7.
49. MHRA. Drug Safety Update Oct 2010, vol 4 issue 3: H2. Available at: http://www.mhra.gov.uk/home/groups/pl-p/documents/publication/con096842.pdf. Accessed 25th September 2011.
50. Labadie J. Postlicensure safety evaluation of human papilloma virus vaccines. Int J Risk Saf Med. 2011;23:103-12.
51. Szarewski A, Poppe W, Skinner SR, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer. 2012;131(1):106-16 doi:10.1002/ijc.26362.
52. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial (Patricia trial). Lancet. 2007;369:2161-70.
53. Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009;5:696-704.
54. Schwarz TFSM, Schneider A, Wysocki J, HPV Study Group for Adult Women, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine. 2009;27:581-7.
55. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366:991-8.
56. Ault KA. Effect of prophylactic human papillomavirus L1 viruslike-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369:1861-8.
57. Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24 Suppl 1:S16-22.
58. Munoz N, Manalastas Jr R, Pitisuttithum PT, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009;373:1949-57.
59. Castellsague X, Munoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011;105:28-37.
60. Cuschieri KS, Horne AW, Szarewski A, Cubie HA. Public awareness of human papillomavirus. J Med Screen. 2006;13:201-7.
61. Skinner SR, Szarewski A, Romanowski B, et al. HPV-16/18 AS04-adjuvanted vaccine efficacy in > 0 26-year-old women after 4-year follow-up. Presented at IPV Conference, Berlin, Sept 17-22, 2011. Abstract number O-18.06.
62. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004;190:2077-87.
63. Coupe VM, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer. 2008;98:646-51.
64. Sellors JW, Karwalajtys TL, Kaczorowski J, et al. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ. 2003;168:421-5.
65. Grainge MJ, Seth R, Guo L, et al. Cervical human papillomavirus screening among older women. Emerg Infect Dis. 2005;11:1680-5.
66. Joura EA, Garland SM, Paavonen J, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012;344:e1401.
67. Michels KB, zur Hausen H. HPV vaccine for all. Lancet. 2009;374:268-70.
68. Kim JJ. Focus on research: weighing the benefits and costs of HPV vaccination of young men. N Engl J Med. 2011;364:393-5.
69. Malmqvist E, Natunen K, Lehtinen M, Helgesson G. Just implementation of human papillomavirus vaccination. J Med Ethics. 2012;38:247-9.
70. Szarewski A. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types. Expert Rev Vaccines. 2012;11(6):645-657. doi:10.1586/erv.12.42.
71. Mehanna H, Jones TM, Gregoire V, Ang KK. Oropharyngeal carcinoma related to human papillomavirus. BMJ. 2010;340:c1439.
72. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis. 2011;204:372-6.
73. Smith MA, Lew JB,Walker RJ, et al. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine. 2011;29:9112-22.
74. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118:2135-45.
75. Petaja T, Keranen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health. 2009;44:33-40.
76. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364:401-11.
77. Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis. 2012;54:891-8.
78. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010;202:1246-53.
79. Levin MJ, Moscicki AB, Song LY, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr. 2010;55:197-204.
80. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7:1374-86.
81. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine. J Natl Cancer Inst. 2011;103:1444-51.
82. Esposito S, Birlutiu V, Jarcuska P, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study. Pediatr Infect Dis J. 2011;30:e49-55.
83. Le Tallec D, Doucet D, Elouahabi A, et al. Cervarix, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions. Hum Vaccin. 2009;5:467-74.
84. Bosch FX. Human papillomavirus: science and technologies for the elimination of cervical cancer. Expert Opinion Pharmacother. 2011;12:2189-204.
85. Schiffman M, Wentzensen N, Wacholder S, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103:368-83.
86. Bosch FX, Castellsague X, de Sanjose S. HPVand cervical cancer: screening or vaccination? Br J Cancer. 2008;98:15-21.